Immunity Against COVID-19 and Safety Following Evusheld (Long-acting Antibody) in Immunocompromised Children and Adolescents
- Conditions
- Immunocompromised Children and AdolescentsEvusheld
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
1. Males or females 5 - < 18 years of age and weights more than or equal 20 kg(s).
2. Participants in a research with immune deficiency and symptoms were stable, classified as malignant or non-malignant.
3. Participants or guardian of participant understand(s) Thai language through speaking, reading and writing
4. Participants or guardian of participant be able
to communicate through electronic tools such as Google form or line.
5. Capable of attending all study visits according to the study schedule.
6. Capable of informed assent/consent and provision of written informed consent before any study procedures
1. Have history of severe drug or vaccine allergy (anaphylaxis)?
2. Have history allergic to the components of the
drug?
3. Participant has an infection or who has the
history of COVID-19 infection within the last 90 days? or who has at higher risk of getting COVID-19
infection.
4. Did not receive any vaccine COVID-19 within 12
weeks before the enrollment?
5. Have any symptoms of acute illness within 3 days
before the enrollment?
6. Be pregnant?
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunological Response 4, 12 and 24 weeks after Evusheld injection IgG level
- Secondary Outcome Measures
Name Time Method Immunological Response 4 week after Evusheld injection Neutralizing antibody assay,Safety 7 days after injection Adverse effects